Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has provided an update.
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s interests following his participation in a recent share placement. Through Kelbury Pty Ltd, where he is a director, Duchini acquired 1,875,000 fully paid ordinary shares at $0.08 per share, increasing his indirect holding to 3,607,456 shares, while his existing 960,000 unlisted options remain unchanged.
The acquisition, valued at $150,000, formed part of a placement previously announced in December 2025 and approved by shareholders in February 2026. The move signals enhanced alignment between the director and shareholders, and underscores management’s confidence in Neurizon Therapeutics’ prospects as it continues to fund its strategic and development initiatives.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company focused on developing therapeutic solutions, likely within the pharmaceutical or life sciences sector. The company operates on the ASX and engages in capital market activities such as share placements to support its development and operational needs.
Average Trading Volume: 598,399
Technical Sentiment Signal: Sell
Current Market Cap: A$59.48M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.